COVID 19 could trigger global diabetes burden – A hypothesis
- 1 September 2020
- journal article
- letter
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 14 (5) , 963-964
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortalityInternational Journal of Antimicrobial Agents, 2020
- COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm?Basic Research in Cardiology, 2020
- Embracing the Landscape of TherapeuticsCell, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- ‘Beauty and the beast’ in infection: How immune–endocrine interactions regulate systemic metabolism in the context of infectionEuropean Journal of Immunology, 2019
- Metabolic Disorders in Chronic Lung DiseasesFrontiers in Medicine, 2018
- Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after InfectionScientific Reports, 2017
- Binding of SARS coronavirus to its receptor damages islets and causes acute diabetesActa Diabetologica, 2009
- Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathwaysThe Journal of Pathology, 2004